Contact:EVC GroupMichael Polyviou/Doug Sherk - Investorsmpolyviou@evcgroup.com; firstname.lastname@example.org; 646-445-4800Thomas Gibson - Mediatom@tomgibsoncommunications.com201-476-0322
WATERTOWN, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker, President and Chief Executive Officer, will present at the Canaccord Genuity 2017 Growth Conference at the InterContinental Boston in Boston, MA. The presentation is scheduled for Thursday, August 10, 2017, at 2:30pm Eastern Time. A live audio and/or webcast and subsequent archived replay of pSivida's presentation may be accessed via the Investors section of the Company's website under "Resources - Events & Presentations" at www.psivida.com. The replay will be available for 90 days after the event. About pSivida Corp.pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the US and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis being independently developed. Two pivotal Phase 3 studies achieved their primary efficacy endpoint at six months of follow-up with statistical significance. pSivida's pre-clinical development program is focused on using its core platform technology Durasert™ to deliver drugs and biologics to treat uveitis, wet age-related macular degeneration, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.